Biogen to pay $22 million for illegally using charities to pay kickbacks to Medicare patients

first_img What is it? About the Author Reprints By Ed Silverman Dec. 17, 2020 Reprints [email protected] AP/Biogen Ed Silverman Log In | Learn More Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED What’s included?center_img GET STARTED Biogen to pay $22 million for illegally using charities to pay kickbacks to Medicare patients Tags biotechnologySTAT+ Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. @Pharmalot STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Biogen (BIIB) has agreed to pay $22 million to resolve allegations that donations it paid to charities were actually kickbacks to Medicare patients used to cover out-of-pockets costs for its multiple sclerosis medicines.This is only the latest instance in which federal authorities have cracked down on such arrangements between drug makers and patient assistance charities. Over the past three years, some of the biggest names in the pharmaceutical industry – including Gilead Sciences (GILD), Pfizer (PFE), Amgen (AMGN), a Johnson & Johnson (JNJ) unit, Sanofi (SNY), and Novartis (NVS) – have reached similar agreements, as have several charities. Pharmalot last_img read more

Continue reading